{
    "symbol": "GALD",
    "slug": "gald",
    "display_name": "GALD",
    "category": "stocks",
    "region": "EU",
    "description": null,
    "url": "https://finscans.com/asset/gald",
    "lang": "en",
    "as_of": "2026-07-01T11:08:06+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 0,
        "bearish": 1,
        "neutral": 0,
        "explicit": 1,
        "inferred": 0,
        "avg_impact": 9,
        "avg_confidence": 95,
        "last_signal_at": "2026-07-01 10:10:05",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "FDA rejection of Relfydess",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Galderma may successfully address FDA concerns rapidly",
            "count": 1
        },
        {
            "text": "Acquisition bid by larger pharma could support shares",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-07-01 10:10:05",
            "sentiment": "Bearish",
            "impact_score": 9,
            "confidence_score": 95,
            "mention_type": "explicit",
            "timeframe": "short-term",
            "region": "EU",
            "reasoning": "FDA rejection of Relfydess directly impacts Galderma's revenue growth prospects and pipeline value, leading to a sharp sell-off in its shares.",
            "article": {
                "title": "Galderma Shares Plunge After FDA Rejects Botox Rival Relfydess",
                "url": "https://finscans.com/news/galderma-shares-plunge-after-fda-rejects-botox-rival"
            }
        }
    ]
}